Goldman Sachs Group Inc.’s private equity arm has agreed to buy a controlling stake in Norgine BV from the specialty pharmaceutical company’s founding Stein family.
The deal was announced in a statement Thursday that confirmed an earlier Bloomberg News report. Financial terms weren’t disclosed. The purchase values Amsterdam-based Norgine at about 1.8 billion euros ($1.9 billion), according to people familiar with the matter.
Norgine, which traces its roots back more than a century, manufactures products including Movicol, Moviprep and Plenvu, drugs used in the treatment of gastrointestinal disorders. Goldman Sachs plans to grow the business in part through mergers and acquisitions.
Read more: BNN Bloomberg
Can't stop reading? This and all news articles are property of their creators, many are not owned or provided by Private Equity Insider. As an event organizer and community platform, we curate content from reliable sources for your suggested reading, and advise you to read the full articles from the referenced authors and sources.